Nifty Test
The NIFTY PRO® test (non-invasive trisomies test) offers screening for up to 18 genetic diseases before birth.
NIFTY PRO® is a safe, simple prenatal test that allows examination as early as 10 weeks. week of pregnancy. Thanks to the latest next-generation sequencing technologies, the NIFTY PRO® test achieves an accuracy of more than 99.5% for the three most common trisomies present at birth – Down syndrome,
99%
precision
The only insured
on the market
99%
precision
The only insured
on the market
NIFTY PRO® is a safe, simple prenatal test that allows examination as early as 10 weeks. week of pregnancy. Thanks to the latest next-generation sequencing technologies, the NIFTY PRO® test achieves an accuracy of more than 99.5% for the three most common trisomies present at birth – Down syndrome,
NIFTY Basic
- Non-invasive prenatal screening that assesses risk 10 most common chromosomal abnormalities fetus in a singleton pregnancy and 6 diseases in twin pregnancy. It also evaluates incidental findings from the blood of a pregnant woman.
- The test is suitable for pregnant women who want to obtain safe and accurate information about the health of the fetus without the risk of invasive procedures.
- Method: Analysis of free fetal DNA (cfDNA) from maternal blood using NGS (Next generation sequencing) with advanced bioinformatics analysis.
NIFTY Pro
- Extended non-invasive prenatal screening from BGI, which, in addition to basic chromosomal abnormalities, also analyzes selected microdeletion and duplication syndromes
- Nifty Pro screens for 102 conditions in singleton pregnancies and 98 conditions in twin pregnancies
- The test is intended for pregnant women who want more comprehensive information without the risk of invasive procedures.
- Method: Whole-genome sequencing of cfDNA from maternal peripheral blood with advanced bioinformatic analysis.
Nifty mono & Nifty pro + 172 diseases
- Nifty mono AR is an expanded non-invasive prenatal screening aimed at, in combination with the Nifty Pro test, screening for up to 102 autosomal recessive monogenic chromosomal diseases (Nifty pro) and 172 autosomal recessive (AR) monogenic diseases.
- Suitable for couples who want the broadest available coverage of screening options without the risk of invasive procedures, while also taking into account the impact of both parents' ages.
- Method: Analysis of free fetal DNA (cfDNA) from maternal blood using NGS (Next generation sequencing) with advanced bioinformatic analysis.
Nifty mono AD & Nifty pro
- o Nifty mono AD is a non-invasive prenatal screening aimed at autosomal dominant monogenic diseases. In combination with NIFTY Pro, it allows the examination of 102 chromosomal diseases and 218 autosomal dominant (AD) monogenic diseases.
- Suitable for couples who want the broadest coverage available for screening options focused on genetic risks to the child, without the risk of invasive procedures.
- Metóda: Cielená sekvenčná analýza vybraných génov z voľnej fetálnej DNA (cfDNA) s detekciou patogénnych variantov.
MONO AR & AD
- Kombinácia genetických testov poskytuje komplexný prehľad o genetickýchrizikách. Zahŕňa skríning až 492 dedičných ochorení, čím pokrýva široké spektrum autozomálne dominantných, autozomálne recesívnych aj viazaných ochorení. Je vhodná pre osoby a páry, ktoré chcú získať čo najpodrobnejšie informácie o svojom genetickom riziku a prenose ochorení na potomstvo.
- Zachytáva ochorenia, ktoré môžu vzniknúť aj bez známej rodinnej anamnézy, ako aj ochorenia podmienené kombináciou genetických variantov oboch rodičov.
- Zohľadňuje genetické riziká súvisiace s vekom rodičov, vrátane veku otca a predstavuje bezpečnú alternatívu bez rizika invazívneho zákroku.
